BIO-TECHNE ($TECH) posted quarterly earnings results on Wednesday, November 5th. The company reported earnings of $0.42 per share, missing estimates of $0.43 by $0.01. The company also reported revenue of $286,560,000, missing estimates of $297,050,673 by $-10,490,673.
You can see Quiver Quantitative's $TECH stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIO-TECHNE Insider Trading Activity
BIO-TECHNE insiders have traded $TECH stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $TECH stock by insiders over the last 6 months:
- ROELAND NUSSE sold 17,040 shares for an estimated $960,388
- ROBERT V BAUMGARTNER sold 17,040 shares for an estimated $957,818
- AMY E. HERR sold 1,280 shares for an estimated $63,704
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BIO-TECHNE Hedge Fund Activity
We have seen 298 institutional investors add shares of BIO-TECHNE stock to their portfolio, and 295 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,527,348 shares (-22.2%) from their portfolio in Q2 2025, for an estimated $130,032,054
- SELECT EQUITY GROUP, L.P. removed 2,446,508 shares (-45.6%) from their portfolio in Q2 2025, for an estimated $125,872,836
- CITADEL ADVISORS LLC added 2,011,189 shares (+437.5%) to their portfolio in Q2 2025, for an estimated $103,475,674
- MILLENNIUM MANAGEMENT LLC added 1,640,649 shares (+inf%) to their portfolio in Q2 2025, for an estimated $84,411,391
- BLACKROCK, INC. removed 1,575,135 shares (-11.5%) from their portfolio in Q2 2025, for an estimated $81,040,695
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,238,095 shares (+inf%) to their portfolio in Q2 2025, for an estimated $63,699,987
- RGM CAPITAL, LLC added 1,189,192 shares (+117.6%) to their portfolio in Q2 2025, for an estimated $61,183,928
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIO-TECHNE Congressional Stock Trading
Members of Congress have traded $TECH stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $TECH stock by members of Congress over the last 6 months:
- REPRESENTATIVE APRIL MCCLAIN DELANEY has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 08/01, 05/26.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BIO-TECHNE Analyst Ratings
Wall Street analysts have issued reports on $TECH in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 10/14/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Citigroup issued a "Buy" rating on 08/21/2025
- Scotiabank issued a "Sector Outperform" rating on 07/11/2025
- Benchmark issued a "Buy" rating on 06/05/2025
- Wells Fargo issued a "Overweight" rating on 05/30/2025
To track analyst ratings and price targets for BIO-TECHNE, check out Quiver Quantitative's $TECH forecast page.
BIO-TECHNE Price Targets
Multiple analysts have issued price targets for $TECH recently. We have seen 8 analysts offer price targets for $TECH in the last 6 months, with a median target of $71.0.
Here are some recent targets:
- Kyle Boucher from TD Cowen set a target price of $70.0 on 10/14/2025
- Daniel Markowitz from Evercore ISI Group set a target price of $72.0 on 10/07/2025
- Conor McNamara from RBC Capital set a target price of $73.0 on 09/03/2025
- Patrick Donnelly from Citigroup set a target price of $70.0 on 08/21/2025
- Sung Ji Nam from Scotiabank set a target price of $75.0 on 07/11/2025
- Robert Wasserman from Benchmark set a target price of $75.0 on 06/05/2025
- Brandon Couillard from Wells Fargo set a target price of $59.0 on 05/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
